Dallas, Texas-based Colossal Biosciences secured $150M funding to advance its genetic engineering software and hardware solutions, and pursue the de-extinction of the Dodo bird.  The Series B round was led by the United States Innovation Technology Fund.  Sources told Bloomberg that the firm was valued at $1.5B at the recent funding round, cementing its status as a unicorn.  Participants in the funding round include Breyer Capital, WestRiver Group, In-Q-Tel, Animoca Brands, and Jazz Ventures.  The funding brings the total raised to date to $225M.  Last year, the firm announced plans to de-extinct the woolly mammoth and Tasmanian tiger.  The de-extinction of the Dodo will be pursued by its newly launched subsidiary, Avian Genomics Group.  Form Bio spun out from Colossal last year and recently raised $30M in Series A funding.